Conversion of non-inferiority margin from hazard ratio to restricted mean survival time difference using data from multiple historical trials

Are restricted mean survival time methods especially useful for noninferiority trials?

(2021) Boris Freidlin et al.   Clinical Trials

Evaluation of the Change of Outcomes over a Ten-Year Period in Patients with Stage III Colon Cancer: Pooled Analysis of 6501 Patients Treated with Fluorouracil, Leucovorin, and Oxaliplatin in the ACCENT Database

(2020) M.E. Salem et al.   ANNALS OF ONCOLOGY

On the empirical choice of the time window for restricted mean survival time

(2020) Lu Tian et al.   BIOMETRICS

Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

(2020) Thierry André et al.   LANCET ONCOLOGY

Multivariate meta-analysis model for the difference in restricted mean survival times

(2019) Isabelle R Weir et al.   BIOSTATISTICS

Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development

(2019) David H. Manner et al.   AMERICAN HEART JOURNAL

Choice of treatment-effect measures when noninferiority margins originally defined in absolute difference translated into relative difference influenced the results of clinical trials

(2018) Xianmixikemaier Abulizi et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

(2018) Axel Grothey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Design of non-inferiority randomized trials using the difference in restricted mean survival times

(2018) Isabelle R Weir et al.   Clinical Trials

Adaptive non-inferiority margins under observable non-constancy

(2018) Brett Hanscom et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer

(2017) Naruhiko Ikoma et al.   JOURNAL OF CLINICAL ONCOLOGY

Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies

(2015) Hajime Uno et al.   ANNALS OF INTERNAL MEDICINE

On the restricted mean survival time curve in survival analysis

(2015) Lihui Zhao et al.   BIOMETRICS

Meta-analysis in clinical trials revisited

(2015) Rebecca DerSimonian et al.   Contemporary Clinical Trials

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According toBRAFMutation and Mismatch Repair Status of the MOSAIC Study

(2015) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY

Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

(2014) Hajime Uno et al.   JOURNAL OF CLINICAL ONCOLOGY

Predicting the restricted mean event time with the subject's baseline covariates in survival analysis

(2013) L. Tian et al.   BIOSTATISTICS

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome

(2013) Patrick Royston et al.   BMC Medical Research Methodology

Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

(2009) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY